Zobrazeno 1 - 10 of 11 pro vyhledávání: '"Aaron Kesselheim"'
2
Patent 'Evergreening' of Medicine–Device Combination Products: A Global Perspective
Autor: Reed Beall, Tali Glazer, Haris Ahmad, Mikayla Buell, Slane Hahn, Adam Houston, Aaron Kesselheim, Jason Nickerson, Warren Kaplan
Publikováno v: Healthcare Policy | Politiques de Santé. 18:14-26
Patenting medicine-delivery devices (inhalers and pens) is controversial when it extends market protections beyond that of the underlying therapeutic agent. We evaluated how common device patenting is, internationally.Using a product sample (n = 88)
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::524bc440f9a093cca6b61e7ac35d85f1
https://doi.org/10.12927/hcpol.2022.26973
Zobrazit plný text záznamu
3
Characteristics of Clinical Trials Evaluating Biosimilars in the Treatment of Cancer: A Systematic Review and Meta-analysis
Autor: Doni Bloomfield, Elvira D’Andrea, Sarosh Nagar, Aaron Kesselheim
Publikováno v: JAMA oncology. 8(4)
Biologics account for almost half of US drug spending but may be subject to competitive pricing pressures by US Food and Drug Administration-approved biosimilars. The extent of the preapproval clinical testing that is needed and how these biosimilars
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e343df644a8aca2e3f16350ad57144f
https://pubmed.ncbi.nlm.nih.gov/35113156
Zobrazit plný text záznamu
5
Alternatives to the quality-adjusted life year: How well do they address common criticisms?
Autor: Leah Rand, G.J. Melendez-Torres, Aaron Kesselheim
Publikováno v: Health services researchREFERENCES.
To analyze whether other outcome measures used in health technology assessment (HTA) address the criticisms of quality-adjusted life years (QALYs).HTA methods guidance from 11 US comparator countries (the G10 and Australia) and six value frameworks f
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16b7f8b171ec179dc84a88332f32e746
https://pubmed.ncbi.nlm.nih.gov/36537647
Zobrazit plný text záznamu
8
Making the Case for Accelerated Withdrawal of Aducanumab
Autor: Peter Whitehouse, Sam Gandy, Vikas Saini, Daniel R. George, Eric B. Larson, G. Caleb Alexander, Jerry Avorn, Shannon Brownlee, Cameron Camp, Howard Chertkow, Adriane Fugh-Berman, Rob Howard, Aaron Kesselheim, Kenneth M. Langa, George Perry, Edo Richard, Lon Schneider
Publikováno v: Journal of Alzheimer's Disease, 87, 1003-1007
Journal of Alzheimer's Disease, 87, 3, pp. 1003-1007
Journal of Alzheimer's Disease, 87(3), 1003-1007. IOS Press
The controversial approval in June 2021 by the Food and Drug Administration (FDA) of aducanumab (marketed as Aduhelm), Biogen’s monoclonal antibody for patients with Alzheimer’s disease, raises significant concerns for the dementia field and drug
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d9f3751407fc056dcf533e597660054e
http://hdl.handle.net/2066/251120
Zobrazit plný text záznamu
9
Predicting Prescribing of Brand-Name vs. Generic Drugs: Machine Learning Analysis with Large-Scale Data (Preprint)
Autor: Jamison Meindl, Rishi Desai, Jessica Franklin, Joyce Lii, Aaron Kesselheim
BACKGROUND The use of brand-name prescription drugs instead of cheaper generic alternatives results in greater rates of cost-related medical nonadherence and poor patient outcomes, as well as higher costs to the health care system. However, because o
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::113d9276457550ab340a81f1d18a92c9
https://doi.org/10.2196/preprints.19605
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje